Skip Navigation LinksHome > July 2009 - Volume 37 - Issue 7 > Intravenous diltiazem is superior to intravenous amiodarone...
Critical Care Medicine:
doi: 10.1097/CCM.0b013e3181a02f56
Continuing Medical Education Article

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation*

Siu, Chung-Wah MBBS; Lau, Chu-Pak MD; Lee, Wai-Luen MBBS; Lam, Kwok-Fai PhD; Tse, Hung-Fat MD, PhD

Continued Medical Education
Collapse Box

Abstract

Objectives: To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization.

Design: Randomized control trial.

Setting: Acute emergency medical admission unit in a regional teaching hospital in Hong Kong.

Patients: One hundred fifty adult patients with acute AF and rapid VR (>120 bpm).

Interventions: Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control.

Measurements and Main Results: The primary end point was sustained VR control (<90 bpm) within 24 hours; the secondary end points included AF symptom improvement and length of hospitalization. At 24 hours, VR control was achieved in 119 of 150 patients (79%). The time to VR control was significantly shorter among patients in the diltiazem group (log-rank test, p < 0.0001) with the percentage of patients who achieved VR control being higher in the diltiazem group (90%) than the digoxin group (74%) and the amiodarone group (74%). The median time to VR control was significantly shorter in the diltiazem group (3 hours, 1–21 hours) compared with the digoxin (6 hours, 3–15 hours, p < 0.001) and amiodarone groups (7 hours, 1–18 hours, p = 0.003). Furthermore, patients in the diltiazem group persistently had the lowest mean VR after the first hour of drug administration compared with the other two groups (p < 0.05). The diltiazem group had the largest reduction in AF symptom frequency score and severity score (p < 0.0001). In addition, length of hospital stay was significantly shorter in the diltiazem group (3.9 ± 1.6 days) compared with digoxin (4.7 ± 2.1 days, p = 0.023) and amiodarone groups (4.7 ± 2.2 days, p = 0.038).

Conclusions: As compared with digoxin and amiodarone, intravenous diltiazem was safe and effective in achieving VR control to improve symptoms and to reduce hospital stay in patients with acute AF.

© 2009 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.